Zobrazeno 1 - 10
of 34
pro vyhledávání: '"F J, Dumont"'
Publikováno v:
The Journal of Immunology. 152:992-1003
Rapamycin (RAP) inhibits several biologic responses in the YAC-1 T cell lymphoma, including the serum-driven proliferation and cyclin A mRNA expression, the induction of Ly-6E Ag expression by IFN, and the induction of IFN-gamma production by IL-1. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb73bcb99fc11f7edc18cb169594a0a9
https://doi.org/10.4049/jimmunol.152.3.992
https://doi.org/10.4049/jimmunol.152.3.992
Autor:
F J Dumont, N H Sigal
Publikováno v:
Annual Review of Immunology. 10:519-560
CsA, FK-506, and rapamycin are microbial products with potent immunosuppressive properties that result primarily from a selective inhibition of T lymphocyte activation. Although chemically unrelated, CsA and FK-506 affect a similar subset of calcium-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77304123db6ea93c2cd114a40a33ba8c
https://doi.org/10.1146/annurev.iy.10.040192.002511
https://doi.org/10.1146/annurev.iy.10.040192.002511
Publikováno v:
The Journal of Immunology. 144:1418-1424
The structurally related immunosuppressive macrolides FK-506 and rapamycin (RAP) were previously shown to inhibit T cell stimulation through different mechanisms. FK-506 acts similarly to cyclosporin A (CsA) and prevents IL-2 production and IL-2R exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c307bc60c4b83a57803310943b28ffa
https://doi.org/10.4049/jimmunol.144.4.1418
https://doi.org/10.4049/jimmunol.144.4.1418
Publikováno v:
The Journal of Immunology. 144:251-258
FK-506 and the structurally related macrolide rapamycin (RAP) were investigated in comparison with cyclosporin A (CsA) for their immunosuppressive effects on murine T cells. All three agents suppressed the proliferation of splenic T cells triggered b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc047e7efdeabe52480934662bffb750
https://doi.org/10.4049/jimmunol.144.1.251
https://doi.org/10.4049/jimmunol.144.1.251
Autor:
F J, Dumont
Publikováno v:
IDrugs : the investigational drugs journal. 2(12)
Bristol-Myers Squibb is developing CTLA4-Ig, an immunosuppressant immunoglobulin, for the potential treatment of various immunological disorders, including graft versus host disease, lupus erythematosus and psoriasis. A phase II trial has commenced f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6be1c844710dba7683d553483b6ac785
https://pubmed.ncbi.nlm.nih.gov/16113966
https://pubmed.ncbi.nlm.nih.gov/16113966
Autor:
F J, Dumont
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 2(9)
Everolimus (RAD-001, SDZ RAD, Certican), an analog of sirolimus, is an oral immunosuppressant that inhibits growth factor-induced cell proliferation, under development by Novartis as a potential treatment for transplant rejection. Phase III trials we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::319775705e9ce7e71a0f2fefe25dd2cb
https://pubmed.ncbi.nlm.nih.gov/11717808
https://pubmed.ncbi.nlm.nih.gov/11717808
Autor:
F J, Dumont
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 2(3)
Due to the improvement in the understanding of the anti-allogenic immune response, the success of transplantation medicine has increased rapidly over the last two decades. The knowledge that the T-lymphocyte played an integral role in transplant reje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2cdacd75d7f22e8052329a4817ae7f1
https://pubmed.ncbi.nlm.nih.gov/11575705
https://pubmed.ncbi.nlm.nih.gov/11575705
Autor:
F J, Dumont
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 2(1)
Alemtuzumab, a lymphocyte-depleting humanized monoclonal antibody, is being developed by Millennium Pharmaceuticals Inc and ILEX Oncology for the potential treatment of chronic lymphocytic leukemia (CLL) [274580]. The utility of the compound for trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72c74452204a2c42821ecaaae35d640d
https://pubmed.ncbi.nlm.nih.gov/11527007
https://pubmed.ncbi.nlm.nih.gov/11527007
Autor:
F J, Dumont, H, Ok, S, Lin, C A, Kastner, J, Cryan, M M, Martin, G, Wiederrecht, M J, Staruch
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 276(3)
FK-506 blocks T cell activation by preventing lymphokine gene transcription through formation of a complex with FKBP12 that inhibits calcineurin phosphatase activity. Immunosuppressive FK-506 analogs (agonists) have been generated whose potency corre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e83efc7f7669392b0d922571c1aee74
https://pubmed.ncbi.nlm.nih.gov/8786538
https://pubmed.ncbi.nlm.nih.gov/8786538
Publikováno v:
Progress in cell cycle research. 1
The immunosuppressant drug, rapamycin (RAP), is a potent inhibitor of IL-2-dependent T-cell proliferation. The antiproliferative effect of RAP is mediated through the formation of an active complex with its cytosolic receptor protein, FKBP12. The mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1bd92b326afa6f7fc6e0ce0f0a058092
https://pubmed.ncbi.nlm.nih.gov/9552353
https://pubmed.ncbi.nlm.nih.gov/9552353